Brief: Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting
17/04/2023 14:09
April 17 (Reuters) - Zentalis Pharmaceuticals Inc
ZNTL.O :
* ZENTALIS ANNOUNCES PRECLINICAL DATA SUPPORTING CYCLIN E1
AS A
PREDICTIVE MARKER FOR AZENOSERTIB TREATMENT AT AACR ANNUAL
MEETING 2023
Source text for Eikon: ID:nGNX5K462y
Further company coverage: ZNTL.O
Recent news on Zentalis Pharmaceuticals
See all newsBrief: Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer